{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:47:13Z","timestamp":1785934033829,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive bile duct destruction, leading to cirrhosis and liver failure. Recent advancements in treatment have focused on targeting specific molecular pathways involved in the disease\u2019s pathogenesis. Iqirvo, a dual peroxisome proliferator-activated receptor alpha and delta agonist, has shown promise in addressing the unmet medical needs of PBC patients. This review examines the clinical development and efficacy of Iqirvo, which recently received accelerated approval from the U.S. Food and Drug Administration. The approval was based on data demonstrating improvements in biochemical markers associated with liver function and bile acid metabolism. We also discuss the safety profile, potential side effects, and future implications for the management of PBC. The expedited approval of Iqirvo represents a significant advancement in PBC therapy, offering new hope for patients unresponsive to existing treatments.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003183","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:12:58Z","timestamp":1742393578000},"page":"2758-2762","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Iqirvo for primary biliary cholangitis \u2013 efficacy, safety, and future directions"],"prefix":"10.1097","volume":"87","author":[{"given":"Rubaisha","family":"Saleem","sequence":"first","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Shakeel","sequence":"additional","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumaisa","family":"Riaz","sequence":"additional","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farwa","family":"Noman","sequence":"additional","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Nasser","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s12072-019-09984-x","article-title":"Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Hepatol Int"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MOG.0000000000000507","article-title":"The genetics of primary biliary cholangitis","volume":"35","author":"Tanaka","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1084\/jem.167.6.1791","article-title":"The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase","volume":"167","author":"Van de Water","year":"1988","journal-title":"J Exp Med"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cca.2010.12.019","article-title":"Disease-specific autoantibodies in primary biliary cirrhosis","volume":"412","author":"Bogdanos","year":"2011","journal-title":"Clin Chim Acta"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2152\/jmi.64.7","article-title":"Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms","volume":"64","author":"Tsuneyama","year":"2017","journal-title":"J Med Invest"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bpg.2018.06.007","article-title":"Symptoms of PBC \u2013 pathophysiology and management","volume":"34\u201335","author":"Khanna","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cld.2018.03.014","article-title":"Chronic complications of cholestasis: evaluation and management","volume":"22","author":"Assis","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/CS20110184","article-title":"Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications","volume":"121","author":"Roma","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","article-title":"Systematic review: ursodeoxycholic acid \u2013 adverse effects and drug interactions","volume":"18","author":"Hempfling","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5604\/16652681.1198824","article-title":"Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction","volume":"15","author":"Bessone","year":"2016","journal-title":"Ann Hepatol"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.21819","article-title":"Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis","volume":"46","author":"Mitro","year":"2007","journal-title":"Hepatology"},{"key":"R25-20260805","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.2015.998650","article-title":"Advances in pharmacotherapy for primary biliary cirrhosis","volume":"16","author":"Mousa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12681","article-title":"Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers","volume":"18","author":"Pencek","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"R31-20260805","first-page":"S34","article-title":"Mechanism of action of fibrates","volume":"69","author":"Shepherd","year":"1993","journal-title":"Postgrad Med J"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cld.2018.03.011","article-title":"Current status of liver transplantation for primary biliary cholangitis","volume":"22","author":"Aguilar","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R38-20260805","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:03:34Z","timestamp":1785931414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003183","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"2024-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}